This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alfa Wassermann SpA
Drug Names(s): Sulodexide, KRX-101
Description: Sulodexide (KRX-101) is a mixture of glycosaminoglycans (GAGs) composed of 80% low molecular weight heparin and 20% dermatan sulfate. Low molecular weight heparincontains the same dimeric components as unfractionated heparin, but has a lower degreeof sulfation and shorter polysaccharide chain length. Dermatan sulfate is apolysaccharide made up of many various disaccharide units.
As a result of the presence of both fractions, Sulodexide potentiatesthe antiprotease activities of both antithrombin III and heparin cofactor II simultaneously. Sulodexide also differs from other GAGs (e.g. heparin) in that it has limited anticoagulant efficacy and can be administered orally.
Deal Structure: Sulonex was originally developed by Keryx Pharmaceuticals.
On August 4, 2009, the Keryx announced that it settled a dispute with Alfa Wassermann over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann will pay Keryx $3,500,000 (of which $2,750,000 was received on July 31, 2009, and $750,000 will be paid on or before July 30, 2010), and Keryx is required to deliver to Alfa Wassermann all of its data, information and other intellectual property related to Sulonex.
Pink Sheet Keryx diabetic nephropathy candidate fails
Additional information available to subscribers only: